MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX)

Historical Holders from Q1 2022 to Q3 2025

Symbol
MLTX on Nasdaq
CUSIP
61559X104
Type / Class
Equity / Class A Ordinary Shares, par value $0.0001 per share
Shares outstanding
63.5M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
37.4M
Holdings value
$268M
% of all portfolios
0.001%
Grand Portfolio weight change
-0.001%
Number of holders
129
Number of buys
76
Number of sells
-85
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.004%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 27.7% $142M 19.8M BVF PARTNERS L P/IL Nov 6, 2025
Deep Track Capital, LP 6.46% $33.1M 4.61M Deep Track Capital, LP Nov 5, 2025
PRICE T ROWE ASSOCIATES INC /MD/ 4.7% -12% $104M -$12.9M 2.97M -11% T. Rowe Price Associates, Inc. Mar 31, 2025
Avoro Capital Advisors LLC 3.15% -47.9% $14.3M -$15.4M 2M -51.8% Avoro Capital Advisors LLC Sep 30, 2025
Chen Bihua 3.14% $108M 1.99M Chen Bihua Sep 30, 2025
FMR LLC 1.1% -87.8% $5.21M -$35.7M 727K -87.3% FMR LLC Sep 30, 2025

Institutional Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 37.4M $268M -$544M $7.17 129
2025 Q2 58.6M $2.77B -$36.6M $47.20 129
2025 Q1 59.7M $2.33B -$153M $39.07 134
2024 Q4 63.2M $3.42B +$68.4M $54.15 114
2024 Q3 62.1M $3.13B +$81M $50.42 111
2024 Q2 60.7M $2.67B +$45.2M $43.97 111
2024 Q1 59.3M $2.98B -$5.58M $50.23 118
2023 Q4 73.1K $4.41M +$2.29M $60.39 1
2023 Q3 56.3M $3.21B +$43.1M $57.00 118
2023 Q2 56.1M $2.86B +$861M $51.00 82
2023 Q1 39.4M $843M +$59.3M $21.39 43
2022 Q4 37.7M $396M +$8.23M $10.50 32
2022 Q3 36.9M $291M +$3.21M $7.76 24
2022 Q2 36.4M $190M +$182M $5.25 21
2022 Q1 654K $7.26M +$7.26M $11.10 1